Casuscelli et al. [7] found increased mutation rates in TP53 (58%) and PTEN (24%) as well as imbalanced chromosome duplication (≥ 3 chromosomes, 25%) in chRCC patients with metastatic disease. The gene discussed is PTEN; the disease is chromophobe renal cell carcinoma.